Leading the way to new and better cancer treatments
About Polaris
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies.
Our lead drug candidate, Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others.
Polaris Group is involved in every stage of the drug development process. Our family of companies harnesses structure-based drug design technology to create novel oncology therapies, conducts clinical studies at top-tier cancer centers worldwide and operates cGMP Production Facilities in Northern California and China.
Clinical Trials
Development and Manufacturing Capabilities
Company News
Global Coalition for Adaptive Research and Polaris Group Announce Commencement of ADI-PEG 20 in GBM AGILE Trial
LARKSPUR, Calif.–(BUSINESS WIRE)–Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris Pharmaceuticals, Inc. (SAN DIEGO, CA), a subsidiary of Polaris Group (TWSE:6550)— The Global Coalition for Adaptive Research (GCAR) in collaboration with Polaris, today announced the activation of ADI-PEG 20 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447).
Polaris Group Appoints Ken Chang, Ph.D., as Chief Strategy Officer and Hugh Yu, Ph.D., as Chief Operating Officer
TAIPEI, Taiwan and SAN DIEGO, Calif., June 13, 2023 — Polaris Group (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases, is proud to announce the appointment of Ken Chang, Ph.D., as Chief Strategy Officer and Hugh Yu, Ph.D., as Chief Operating Officer.
Polaris Group’s Affiliate Nanotein Technologies Launches a Revolutionary NK Cell Activation and Expansion Reagent
TAIPEI, Taiwan and VACAVILLE, Calif., June 07, 2023— Polaris Group (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases, today announced that Polaris Group’s affiliate, Nanotein Technologies, has just launched GROW-NK, a novel Natural Killer (NK) cell activation and expansion reagent.
Polaris Group Presents Positive Phase 2/3 data for ADI-PEG 20, First-in-Class Arginine Depletion therapy in Patients with Malignant Pleural Mesothelioma at AACR Annual Meeting 2023
TAIPEI, Taiwan and SAN DIEGO, Calif., April 16, 2023 — Polaris Group (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases, today presented data from its Phase 2/3 ATOMIC Study, a global, multi-center, randomized, double-blind, placebo-controlled trial of ADI-PEG 20 in combination with Pemetrexed and Cisplatin in patients with unresectable Malignant Pleural Mesothelioma (MPM) with biphasic or sarcomatoid histology.